More
Keymed and Lepu Biopharma Jointly Announce Global Exclusive Licence Agreement with AstraZeneca for CMG901
KYM Biosciences, the joint venture established by Keymed and Lepu Biopharma, on transaction closing and additional development and sales-related milestone payments of up to $1 1bn as well as tiered royalties up to low double-digits
2023-02-23